Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children.
CONCLUSION: This analysis provides clinical evidence that the modified manufacturing process improved the fever profile across all pediatric age groups, in particular, in children aged <5 years.
PMID: 30935743 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Sawlwin DC, Graves Jones A, Albano FR Tags: Vaccine Source Type: research
More News: Allergy & Immunology | Children | History of Medicine | Influenza | Influenza Vaccine | Pediatrics | Science | Sodium | Study | Vaccines